Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has provided an announcement.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that it and its subsidiary, Innogen Technology, have subscribed to a structured deposit product from the Bank of Ningbo for RMB105,000,000. This move is part of the company’s strategy to maximize returns on idle funds through low-risk investments in wealth management products issued by reputable banks in China. The structured deposit offers an expected annualized return between 0.5% and 1.8%, and is intended for treasury management purposes, ensuring sufficient working capital for the company’s operational needs.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a holding company primarily engaged in the research, development, and commercialization of pharmaceutical products. Innogen Technology, a subsidiary, focuses on pharmaceutical research, development, and production.
Average Trading Volume: 1,039,000
For an in-depth examination of 2591 stock, go to TipRanks’ Overview page.